Remon and colleagues also reported, in their prior prospective analysis, that osimertinib achieved a 62.5% response rate in NSCLC cases with the EGFR T790M mutation based on ctDNA analysis, and that this efficacy was comparable to cases with the EGFR T790M mutation detected in a tissue biopsy [38]. Here, EGFR is linked to non-small cell lung carcinoma.